Literature DB >> 5163179

Metabolism of fibrinogen in cirrhosis of the liver.

G N Tytgat, D Collen, M Verstraete.   

Abstract

The metabolism of human fibrinogen labeled with radioactive iodine was studied in 50 patients with documented cirrhosis of the liver and in 35 healthy control subjects. Results in cirrhotic subjects were the following: plasma volume 47 +/- 10 ml/kg; plasma fibrinogen concentration 250 +/- 102 mg/100 ml; total plasma fibrinogen pool 118 +/- 59 mg/kg, representing 0.73 +/- 0.10 of the total body pool; fibrinogen half-life 2.99 +/- 0.59 days; fractional catabolic rate 0.34 +/- 0.09 of the plasma pool per day; absolute catabolic rate 39 +/- 20 mg/kg per day; fractional transcapillary efflux rate 0.82 +/- 0.30 of the plasma pool per day. Results in the control subjects were the following: plasma volume 42 +/- 7 ml/kg; plasma fibrinogen concentration 284 +/- 71 mg/100 ml; total plasma fibrinogen pool 119 +/- 40 mg/kg, representing 0.72 +/- 0.07 of the total body pool; fibrinogen half-life 4.14 +/- 0.56 days; fractional catabolic rate 0.24 +/- 0.04 of the plasma pool per day; absolute catabolic rate 28 +/- 9 mg/kg per day; fractional transcapillary efflux rate 0.60 +/- 0.26 of the plasma pool per day.A significant difference between cirrhotics and controls was observed for plasma volume, fibrinogen half-life, fractional and total catabolic rates, and transcapillary efflux rate. During heparinization of 10 cirrhotic patients the fibrinogen half-life was prolonged from 3.15 +/- 0.69 to 4.59 +/- 0.79 days. This was associated with a rise in plasma fibrinogen in six out of eight patients. Heparinization did not influence the fibrinogen half-life in five control subjects. Inhibition of the fibrinolytic system in 17 patients resulted in prolongation of the plasma radioactivity half-life of more than 1 day in only three patients, an incidence comparable with that in five control subjects. These results strongly support the concept of accelerated fibrinogen consumption by a process of disseminated intravascular coagulation in cirrhosis of the liver.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5163179      PMCID: PMC442069          DOI: 10.1172/JCI106658

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  56 in total

1.  SPUR-CELL ANEMIA: HEMOLYTIC ANEMIA WITH RED CELLS RESEMBLING ACANTHOCYTES IN ALCOHOLIC CIRRHOSIS.

Authors:  J A SMITH; E T LONERGAN; K STERLING
Journal:  N Engl J Med       Date:  1964-08-20       Impact factor: 91.245

2.  A rapid enzymatic method for assay of fibrinogen fibrin polymerization time (FPT test).

Authors:  C VERMYLEN; R A DE VREKER; M VERSTRAETE
Journal:  Clin Chim Acta       Date:  1963-05       Impact factor: 3.786

3.  Biosynthetic determination with radioactive sulfur of turn-over rates of various plasma proteins in normal and cirrhotic man.

Authors:  W VOLWILER; P D GOLDSWORTHY; M P MACMARTIN; P A WOOD; I R MACKAY; K FREMONT-SMITH
Journal:  J Clin Invest       Date:  1955-07       Impact factor: 14.808

4.  Circulatory changes in chronic liver disease.

Authors:  J F MURRAY; A M DAWSON; S SHERLOCK
Journal:  Am J Med       Date:  1958-03       Impact factor: 4.965

5.  The preparation of proaccelerin deficient (parahemophilia) plasma for the assay of proaccelerin.

Authors:  H STORMORKEN
Journal:  Scand J Clin Lab Invest       Date:  1957       Impact factor: 1.713

6.  Consumption coagulopathy in liver cirrhosis.

Authors:  M H Hörder
Journal:  Thromb Diath Haemorrh Suppl       Date:  1969

7.  Microangiopathic haemolytic anaemia: the experimental production of haemolysis and red-cell fragmentation by defibrination in vivo.

Authors:  M L Rubenberg; E Regoeczi; B S Bull; J V Dacie; M C Brain
Journal:  Br J Haematol       Date:  1968-06       Impact factor: 6.998

8.  The uptake of fibrin and fibrin-degradation products by the isolated perfused rat liver.

Authors:  H Gans; J T Lowman
Journal:  Blood       Date:  1967-04       Impact factor: 22.113

9.  The defibrination syndrome: clinical features and laboratory diagnosis.

Authors:  C Merskey; A J Johnson; G J Kleiner; H Wohl
Journal:  Br J Haematol       Date:  1967-07       Impact factor: 6.998

10.  SERUM ALBUMIN TURNOVER IN NORMAL SUBJECTS AND PATIENTS WITH CIRRHOSIS MEASURED BY 131I-LABELLED HUMAN ALBUMIN.

Authors:  P WILKINSON; C L MENDENHALL
Journal:  Clin Sci       Date:  1963-10       Impact factor: 6.124

View more
  10 in total

1.  Complex pharmacokinetics of a humanized antibody against human amyloid beta peptide, anti-abeta Ab2, in nonclinical species.

Authors:  Yulia Vugmeyster; Pam Szklut; David Wensel; John Ross; Xin Xu; Michel Awwad; Davinder Gill; Lioudmila Tchistiakov; Garvin Warner
Journal:  Pharm Res       Date:  2011-03-18       Impact factor: 4.200

2.  Dysfibrinogenemia associated with liver disease.

Authors:  J E Palascak; J Martinez
Journal:  J Clin Invest       Date:  1977-07       Impact factor: 14.808

3.  Fibrinogen measurement in liver disease: validation of the functional fibrinogen thromboelastography assay and a novel mathematical predictive model.

Authors:  Kirsty Rizzo; Kevin Vella; Daniel Zammit; Peter Gatt; Charlie Grima; Monique Borg Inguanez; Jurgen Gerada; Pierre Ellul; Mario Vassallo; Neville Azzopardi; James Pocock; Alex Gatt
Journal:  Blood Transfus       Date:  2018-11-09       Impact factor: 3.443

4.  [Endogenous inhibitors of fibrinolytic activity in liver cirrhosis (author's transl)].

Authors:  R Aschauer; F Holzknecht; S Platzer
Journal:  Klin Wochenschr       Date:  1973-12-01

5.  Studies on hemorrhagic tendency in cirrhosis of the liver.

Authors:  R Yoshimura; H Asai; S Harihara; T Kamata; T Monna; S Yamamoto; T Fukuda; H Maeda
Journal:  Gastroenterol Jpn       Date:  1979-08

6.  The influence of antithrombin III (AT III) substitution to supranormal activities on systemic procoagulant turnover in patients with end-stage chronic liver disease.

Authors:  R Scherer; M Kabatnik; J Erhard; J Peters
Journal:  Intensive Care Med       Date:  1997-11       Impact factor: 17.440

7.  Antithrombin III metabolism in patients with liver disease.

Authors:  E Knot; J W Ten Cate; H R Drijfhout; L H Kahlé; G N Tytgat
Journal:  J Clin Pathol       Date:  1984-05       Impact factor: 3.411

8.  Antithrombin III, plasminogen and alpha 2 antiplasmin in jaundice. Clinical usefulness and prognostic significance.

Authors:  J J Rodzynek; D Urbain; P Leautaud; P Wettendorff; A Delcourt
Journal:  Gut       Date:  1984-10       Impact factor: 23.059

9.  Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS-MS.

Authors:  Asem I Fitian; David R Nelson; Chen Liu; Yiling Xu; Miguel Ararat; Roniel Cabrera
Journal:  Liver Int       Date:  2014-04-28       Impact factor: 5.828

10.  Intraperitoneal coagulation in chronic liver disease ascites.

Authors:  J Hoefs; T Barnes; P Halle
Journal:  Dig Dis Sci       Date:  1981-06       Impact factor: 3.199

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.